MX2009013948A - Derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b] piridazina, su preparacion y uso terapéutico. - Google Patents

Derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b] piridazina, su preparacion y uso terapéutico.

Info

Publication number
MX2009013948A
MX2009013948A MX2009013948A MX2009013948A MX2009013948A MX 2009013948 A MX2009013948 A MX 2009013948A MX 2009013948 A MX2009013948 A MX 2009013948A MX 2009013948 A MX2009013948 A MX 2009013948A MX 2009013948 A MX2009013948 A MX 2009013948A
Authority
MX
Mexico
Prior art keywords
group
groups
optionally substituted
cycloamino
imidazo
Prior art date
Application number
MX2009013948A
Other languages
English (en)
Inventor
Antonio Almario Garcia
Pascal George
Philippe Burnier
Frederic Puech
Adrien Tak Li
Matthieu Barrague
Cecile Enguehard
Zhongli Gao
Alain Gueiffier
Roy Vaz
Qiuxia Zhao
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MX2009013948A publication Critical patent/MX2009013948A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La presente invención se refiere a derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina que corresponden a la fórmula general de (I), en el cual cuya fórmula (I) R2 es un grupo arilo opcionalmente substituido por uno o más substituyentes seleccionados de los átomos de halógeno, y C1-6 alquilo, C1-6 alquiloxi, C1-6 alquiltio, C1-6 fluoroalquilo, C1-6 fluoroalquiloxi y grupos -CN; R3 es un átomo de hidrógeno o un C1-3 alquilo, -NR4R5, hidroxilo o un grupo C1-4 alquiloxi; -A es un grupo C1-7 alquileno opcionalmente substituido por uno o dos grupos Ra; B es un grupo C1-7 alquileno opcionalmente substituido por un grupo Ra; L es cualquiera de un átomo de nitrógeno opcionalmente substituido por un grupo R, o Ra o un átomo de carbono substituido por un grupo R y un grupo Ra o dos grupos Re2; los átomos de carbono de A y de B o de los grupos Re2 son opcionalmente substituidos por uno o más grupos Rf los cuales pueden ser idénticos o diferentes entre ellos; R7 y Ra son, independientemente entre ellos, un átomo de hidrógeno o un grupo C1-6-alquilo. Método de preparación y uso terapéutico.
MX2009013948A 2007-06-28 2008-06-26 Derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b] piridazina, su preparacion y uso terapéutico. MX2009013948A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94678507P 2007-06-28 2007-06-28
FR0704661A FR2918061B1 (fr) 2007-06-28 2007-06-28 Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique.
PCT/FR2008/000902 WO2009016286A2 (fr) 2007-06-28 2008-06-26 Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo[1, 2-b]-pyridazine, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
MX2009013948A true MX2009013948A (es) 2010-03-09

Family

ID=39203151

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013948A MX2009013948A (es) 2007-06-28 2008-06-26 Derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b] piridazina, su preparacion y uso terapéutico.

Country Status (22)

Country Link
US (2) US8354405B2 (es)
EP (1) EP2170889B1 (es)
JP (1) JP5537424B2 (es)
KR (1) KR20100050492A (es)
CN (1) CN101765602A (es)
AR (1) AR069269A1 (es)
AU (1) AU2008281662A1 (es)
BR (1) BRPI0814807A2 (es)
CA (1) CA2691866A1 (es)
CL (1) CL2008001932A1 (es)
CO (1) CO6251269A2 (es)
EA (1) EA201070072A1 (es)
FR (1) FR2918061B1 (es)
MA (1) MA31572B1 (es)
MX (1) MX2009013948A (es)
NZ (1) NZ582677A (es)
PA (1) PA8786101A1 (es)
PE (1) PE20090556A1 (es)
TW (1) TW200911812A (es)
UY (1) UY31193A1 (es)
WO (1) WO2009016286A2 (es)
ZA (1) ZA200909186B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7868001B2 (en) * 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
ES2548135T3 (es) 2008-05-13 2015-10-14 Novartis Ag Heterociclos condensados que contienen nitrógeno y composiciones de los mismos como inhibidores de quinasa
FR2934994B1 (fr) * 2008-08-12 2010-09-17 Sanofi Aventis Derives de 2-alkyl-6cycloamino-3-(pyridin-4-yl)imidaz°1,2-b! pyridazine, leur preparation et leur application en therapeutique
FR2939134A1 (fr) * 2008-12-01 2010-06-04 Sanofi Aventis Derives de 6-cycloamino-3-(1h-pyrrolo°2,3-b!pyridin-4-yl) imidazo°1,2-b!-pyridazine, leur preparation et leur application en therapeutique
FR2940285A1 (fr) * 2008-12-19 2010-06-25 Sanofi Aventis Derives de 6-cycloamino-2-thienyl-3-(pyridin-4-yl)imidazo °1,2-b!-pyridazine et 6-cycloamino-2-furanyl-3- (pyridin-4-yl)imidazo°1,2-b!-pyridazine, leur preparation et leur application en therapeutique
FR2940284B1 (fr) * 2008-12-19 2011-02-18 Sanofi Aventis Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique
JP5848251B2 (ja) 2009-10-23 2016-01-27 ヤンセン ファーマシューティカ エヌ．ベー． オレキシン受容体調節因子としての縮合複素環式化合物
WO2011050200A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
JO3267B1 (ar) * 2009-10-23 2018-09-16 Janssen Pharmaceutica Nv بيرولات [3، 4-سي] اوكتاهيدروبيرولو ثنائية الاستبدال كمعدلات لمستقبل اوريكسين
CN102596961B (zh) 2009-10-30 2015-12-02 詹森药业有限公司 咪唑并[1，2-b]哒嗪衍生物及其作为PDE10抑制剂的用途
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
EP2560637B1 (en) 2010-04-06 2018-11-07 Fred Hutchinson Cancer Research Center Methods for identifying and using inhibitors of casein kinase 1 epsilon isoform for inhibiting the growth and/or proliferation of myc-driven tumor cells
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
ES2553610T3 (es) * 2010-12-14 2015-12-10 Electrophoretics Limited Inhibidores de la caseína cinasa 1 delta (CK1delta)
TWI617559B (zh) 2010-12-22 2018-03-11 江蘇恆瑞醫藥股份有限公司 ２－芳基咪唑并［１，２－ｂ］嗒．２－苯基咪唑并［１，２－ａ］吡啶，和２－苯基咪唑并［１，２－ａ］吡衍生物
WO2012145581A1 (en) 2011-04-20 2012-10-26 Janssen Pharmaceutica Nv Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
BR112013033375B1 (pt) 2011-06-27 2022-05-10 Janssen Pharmaceutica N.V Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário
US9273317B2 (en) 2011-08-09 2016-03-01 Fred Hutchinson Cancer Research Center Methods and compositions for inhibiting the growth and/or proliferation of MYC-driven tumor cells
CA2872216C (en) 2012-06-26 2021-07-20 Janssen Pharmaceutica Nv Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl-[1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
NZ702618A (en) 2012-06-27 2016-12-23 4Sc Discovery Gmbh Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders
WO2014009305A1 (en) 2012-07-09 2014-01-16 Janssen Pharmaceutica Nv Inhibitors of phosphodiesterase 10 enzyme
CZ2012538A3 (cs) * 2012-08-08 2014-02-19 Masarykova Univerzita Inhibitory pro léčbu B-buněčné chronické lymfocytární leukémie
US10676746B2 (en) 2013-11-22 2020-06-09 Fred Hutchinson Cancer Research Center Methods for identifying therapeutic targets and treating monitoring cancers
AU2015204566A1 (en) * 2014-01-09 2016-08-25 Intra-Cellular Therapies, Inc. Organic compounds
JP2017506259A (ja) 2014-02-03 2017-03-02 イッスム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッドＹｉｓｓｕｍ Ｒｅｓｅａｒｃｈ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏｍｐａｎｙ Ｏｆ Ｔｈｅ Ｈｅｂｒｅｗ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｊｅｒｕｓａｌｅｍ Ｌｔｄ． 幹細胞を枯渇させるためのカゼインキナーゼｉ阻害剤の使用
ES2913469T3 (es) 2016-03-10 2022-06-02 Janssen Pharmaceutica Nv Métodos para tratar la depresión usando antagonistas del receptor de orexina-2
EP4101853A1 (en) 2017-03-14 2022-12-14 Daiichi Sankyo Company, Limited Method for producing 3,6-disubstituted-imidazo[1,2-b]pyridazine derivative
TW202244048A (zh) 2017-03-20 2022-11-16 美商佛瑪治療公司 作為丙酮酸激酶（ｐｋｒ）活化劑之吡咯并吡咯組成物
US10973820B2 (en) * 2017-12-13 2021-04-13 Facio Intellectual Property B.V. Compounds for treatment of diseases related to DUX4 expression
BR112021005188A2 (pt) 2018-09-19 2021-06-08 Forma Therapeutics, Inc. tratamento de anemia falciforme com um composto de ativação de piruvato cinase r
US20230055923A1 (en) 2018-09-19 2023-02-23 Forma Therapeutics, Inc. Activating pyruvate kinase r
WO2020151682A1 (zh) * 2019-01-23 2020-07-30 成都先导药物开发股份有限公司 一种大环类免疫调节剂
TW202112368A (zh) * 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 用於治療有關dux4表現之疾病的抑制劑組合
US11193891B2 (en) 2019-12-20 2021-12-07 Robert Bosch Gmbh Receptors and spacers for a fluorescence-based lead ion chemosensor
EP4126878A1 (en) * 2020-03-27 2023-02-08 Gritscience Biopharmaceuticals Co., Ltd. Compounds as casein kinase inhibitors
WO2021190616A1 (en) * 2020-03-27 2021-09-30 Gritscience Biopharmaceuticals Co., Ltd. Methods for inhibiting casein kinases
AU2022367432A1 (en) 2021-10-14 2024-05-02 Incyte Corporation Quinoline compounds as inhibitors of kras

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0103926D0 (en) * 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
EP1388541A1 (en) * 2002-08-09 2004-02-11 Centre National De La Recherche Scientifique (Cnrs) Pyrrolopyrazines as kinase inhibitors
RS50823B (sr) * 2003-12-11 2010-08-31 Aventis Pharmaceuticals Inc. Supstituisani 1h-pirolo[3,2-b, 3,2-c, i 2,3-c]piridin-2-karboksamidi i srodni analozi kao inhibitori kazein kinaze i epsilon
EP1790650B1 (en) * 2004-08-31 2014-03-26 Msd Kk NEW SUBSTITUTED IMIDAZOLE DERIVATIVES
JPWO2006070943A1 (ja) * 2004-12-28 2008-06-12 武田薬品工業株式会社 縮合イミダゾール化合物およびその用途
US20100216798A1 (en) * 2005-07-29 2010-08-26 Astellas Pharma Inc Fused heterocycles as lck inhibitors
EP1845098A1 (en) * 2006-03-29 2007-10-17 Ferrer Internacional, S.A. Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands
BRPI0718029A2 (pt) * 2006-11-06 2013-11-26 Supergen Inc Derivados de imidazo(1,2-b)piridazina e pirazolo(1,5-a)pirimidina e seu uso como inibidores da proteína cinase
AR064420A1 (es) * 2006-12-21 2009-04-01 Alcon Mfg Ltd Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).

Also Published As

Publication number Publication date
WO2009016286A3 (fr) 2009-04-09
US8846676B2 (en) 2014-09-30
JP2010531342A (ja) 2010-09-24
BRPI0814807A2 (pt) 2015-02-03
NZ582677A (en) 2011-12-22
CA2691866A1 (fr) 2009-02-05
PA8786101A1 (es) 2009-01-23
EP2170889A2 (fr) 2010-04-07
FR2918061B1 (fr) 2010-10-22
TW200911812A (en) 2009-03-16
CN101765602A (zh) 2010-06-30
EP2170889B1 (fr) 2016-08-17
CO6251269A2 (es) 2011-02-21
AR069269A1 (es) 2010-01-13
EA201070072A1 (ru) 2010-08-30
PE20090556A1 (es) 2009-06-01
MA31572B1 (fr) 2010-08-02
CL2008001932A1 (es) 2009-09-25
AU2008281662A1 (en) 2009-02-05
UY31193A1 (es) 2009-01-30
JP5537424B2 (ja) 2014-07-02
KR20100050492A (ko) 2010-05-13
WO2009016286A2 (fr) 2009-02-05
FR2918061A1 (fr) 2009-01-02
US20130012516A1 (en) 2013-01-10
ZA200909186B (en) 2011-02-23
US8354405B2 (en) 2013-01-15
US20100179154A1 (en) 2010-07-15

Similar Documents

Publication Publication Date Title
MX2009013948A (es) Derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b] piridazina, su preparacion y uso terapéutico.
WO2009037394A3 (fr) DERIVES DE 6-CYCLOAMINO-S-(PYRIDAZIN-YL)IMIDAZO[1,2-b]-PYRIDAZINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE.
WO2009144394A8 (fr) Derives de 2-aryl-6-phenyl-imidazo[1,2-a]pyridines polysubstitues, leur préparation et leur application en thérapeutique
UA95976C2 (en) 2-ARYL-6-PHENYLIMIDAZO[1,2-b]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
MX2013007148A (es) 2-arilimidazo[1,2-b]piridazina, 2-fenilimidazo[1,2-a]pirimidina, y derivados de 2-fenilimidazo[1.2-a]pirazina.
MX2010003445A (es) Derivados de nicotinamida, su preparacion y su uso terapeutico.
NZ608718A (en) Imidazo[1,2-b]pyridazine and imidazo[4,5-b]pyridine derivatives as jak inhibitors
WO2009112678A3 (fr) Derives de carboxam i d es azabicycliques, leur preparation et leur application en therapeutique.
WO2009144395A8 (fr) DÉRIVÉS POLYSUBSTITUES DE 2-HETEROARYL-6-PHENYL-IMIDAZO[1,2- α]PYRIDINES, LEUR PRÉPARATION ET LEUR APPLICATION EN THÉRAPEUTIQUE
MX2010007976A (es) Derivados de carboxamidas n-azabiciclicas, su preparacion y su aplicacion en terapeutica.
EA201071111A1 (ru) ПОЛИЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 6-ГЕТЕРОАРИЛИМИДАЗО[1,2-a]ПИРИДИНОВ, ИХ ПОЛУЧЕНИЕ И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ
TN2012000608A1 (en) Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof
MX2010003394A (es) Derivado de gamma-aminoacido biciclico.
MA32246B1 (fr) Dérivés polysubstitues de 2-aryl-6-phenyl-imidazo[1,2- a]pyridines, leur préparation et leur application en thérapeutique
WO2010130934A3 (fr) Derives de 2-cycloamino-5-(pyridin-4-yl)imidazo[2,1-b][1,3,4]thiadiazole, leur preparation et leur application en therapeutique
MX2013005734A (es) Derivados de heteroarilsulfonamidas, su preparacion y su aplicacion en terapia humana.
MX2009007682A (es) Compuestos de 6-bencil-2,3,4,7-tetrahidro-indolo[2,3-c] quinolina utiles como inhibidor de de5.
TW200728303A (en) N-(arylalkyl)-1H-pyrrolopyridine-2-carboxamide derivatives, preparation thereof and therapeutic use thereof
TN2012000520A1 (en) 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide derivatives, preparation thereof and therapeutic use thereof
WO2010011546A3 (en) Pyrrolo [3, 2-b]pyridines and pyrazolo [4, 3 -b] pyridines having 5-ht6 receptor affinity
PA8854501A1 (es) "DERIVADOS DE 6-CICLOAMINO-2-TIENTI-3-(PIRINDIN-4-IL)IMIDAZO(1,2-B)-PIRIDAZINA Y 6-CICLOAMINO-2-FURANIL-3-(PIRIDIN-4-IL)IMIDAZO)1,2-b)-PIRIDAZINA, SU PREPARACIÓN Y SU APLICACIÓN EN TERAPEUTICA."
RS54656B1 (en) 6-CYCLOAMINO-3- (1H-Pyrrolo [2,3-B] pyridin-4-yl) IMIDAZO [1,2-B] Pyridazine derivatives, their preparation and use in therapy
WO2009106750A3 (fr) Dérivés 6-heterocyclique-imidazo[1,2-a]pyrroine-2-carboxamides, leur préparation et leur application en thérapeutique
MX2010007348A (es) Derivados de n-fenil-imidazo[1,2-a]piridin-2-carboxamidas, su preparacion y su aplicacion terapeutica.
WO2009106751A3 (fr) Dérivés de n-heterocyclique-6-heterocyclique-imidazo[1,2- a]pyridiνe-2-carb0xamides, leur préparation et leur application en thérapeutique

Legal Events

Date Code Title Description
HH Correction or change in general